key: cord-1017622-39kiuqf8
authors: Singh‐Grewal, Davinder; Lucas, Ryan; McCarthy, Kristine; Cheng, Allen C; Wood, Nicholas; Ostring, Genevieve; Britton, Philip; Crawford, Nigel; Burgner, David
title: Update on the COVID‐19‐associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome‐temporally associated with SARS‐CoV‐2
date: 2020-07-31
journal: J Paediatr Child Health
DOI: 10.1111/jpc.15049
sha: 0016b42bcac1d327bd32513990c2e654ba2933fd
doc_id: 1017622
cord_uid: 39kiuqf8

We provide an update on the state of play with regards a newly described inflammatory condition which has arisen during the current SARS‐CoV‐2 pandemic. The condition has been named paediatric inflammatory multisystem syndrome temporally associated with SARS‐CoV‐2 or multisystem inflammatory syndrome in children. This condition has shown significant similarities to Kawasaki disease and toxic shock syndrome.

Paediatricians and many families are aware of the recent reports of a novel multisystem inflammatory syndrome in children (MIS-C), which appears related to the ongoing SARS-CoV-2 pandemic. The condition has been named paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) by the European Centre for Disease Prevention and Control 1 and MIS-C by the Centres for Disease Control and Prevention in the USA 2 and World Health Organization. 3 Henceforth, we use the term PIMS-TS to denote both of these described entities.

PIMS-TS was first reported in the UK in late April through the European Union's Early Warning and Response System and has now been reported from other European centres, the USA and Middle East. Anecdotally, up to 1000 cases have been reported formally and informally. Fewer than 10 deaths have been publicly reported to date. No confirmed cases have been reported in Australia or New Zealand to date.

Overall, the reported infection rates with SARS-CoV-2 (the novel coronavirus) are lower in children than adults, and children are often asymptomatic or have comparatively milder acute manifestations. 4 Few children have required hospitalisation or intensive care admission as part of the acute infection. 5 Rather than a manifestation of primary infection, PIMS-TS appears to be a severe but delayed immune response to SARS-CoV-2 infection with uncontrolled inflammation resulting in host tissue damage. 6 The finding that many children with PIMS-TS have positive SARS-CoV-2 serology but are PCR negative on nasopharyngeal swabs supports the hypothesis of a post-infectious phenomenon. [7] [8] [9] This is also supported by the observation that the peak in PIMS-TS cases lags behind the peak in acute SARS-COV-2 cases by some weeks. 7 The mechanisms are unknown, but it seems plausible that genetic variation in affected children may contribute to this rare syndrome. Both innate (nonspecific) and adaptive (both humoral and T-cell mediated) arms of the immune system have been suggested to be involved. 9, 10 A striking feature of PIMS-TS is the overlap with Kawasaki disease (KD) and toxic shock syndrome (TSS), both vasculitides likely triggered by infection. 9 While SARS-COV-2 is the suspected aetiological agent causing PIMS-TS, the cause of KD is unknown and may involve more than one infectious trigger. 11 Interestingly another novel coronavirus (coronavirus New Haven -HCoV-NH/ HCoV-NL63) was previously implicated as the possible cause of KD in a series of cases in 2005, 11 but this finding could not be substantiated in other populations. 12 Children with PIMS-TS seem to present with a severe illness characterised by shock and features often seen in KD or Kawasaki shock syndrome (KSS) (a rare, more severe form of KD that shares features with TSS). 13 These features include prolonged fever, rash, conjunctival injection, mucosal changes and raised inflammatory markers. While these features are common to both KSS and TSS, the inflammation seen in PIMS-TS seems to be far greater than that of KD. [7] [8] [9] 13 Other differentiating features of PIMS-TS include an older age of onset (average of 10 years compared to 2 years for KD) and abdominal pain and diarrhoea as prominent presenting symptoms; myocardial and renal dysfunction have also been reported. [7] [8] [9] 13 Additionally, children with PIMS-TS have shown marked lymphopaenia and thrombocytopaenia, coagulopathy, raised cardiac enzymes (troponin and brain natriuretic peptide, BNP), hyponatraemia, Gastrointestinal Abdominal symptoms (pain, diarrhoea, vomiting) common 18, 20 Abdominal symptoms (pain, diarrhoea, vomiting)more common than in KD 20 Vomiting, diarrhoea, abdominal pain 28 Diarrhoea in 50-87% 9, 13 Abdominal pain in 50-75% 9, 13 Musculoskeletal Arthralgia and arthritis common 18 As for KD Myalgia +++ 28 Myalgia in 1/8 13

Irritability common 18 As for KD Headache, confusion 28 Headache in 25-25% 9,13 Renal Acute renal failure rare 20 Acute renal failure more common than in KD 20

Acute renal failure common 29 22% with acute renal injury 9 and 1/8 required renal replacement therapy 13 Echocardiogram findings Coronary changes 5-25% 22 2-3 times more common than KD 20, 27 No data 14% have coronary lesions 9 Giant aneurysms in 12-25% 9, 13 (Continues) hypoalbuminaemia and raised lactate dehydrogenase and ferritin;

these features have only infrequently been reported in KD. [7] [8] [9] Early reports suggest that 20-25% of PIMS-TS patients demonstrate coronary artery changes (similar to the rate in untreated KD 13 ); however giant coronary artery aneurysms were uncommon (<4%), 9 and most lesions have resolved relatively promptly (over a few weeks) with treatment. 7, 8, 13 As paediatricians are aware, KD has a much higher incidence in children of North East Asian ancestry 14, 15 ; it is notable that PIMS-TS has not yet been reported from Asia. Cases of PIMS-TS reported to date have shown a possible over-representation of children from African, African-American and Afro-Caribbean ancestry. 9, 12 Hypothesised explanations for this observation include the effect of relative social disadvantage on disease exposure and transmission, as well as the possibility of a specific genetic predisposition to PIMS-TS (analogous but distinct from that contributing to the ethnic differences in KD incidence 15 ).

Patients with PIMS-TS have often required supportive treatment for hypotension and circulatory collapse. [7] [8] [9] 13 Intravenous immunoglobulin (also the primary treatment for KD) and corticosteroids have also been used extensively, [7] [8] [9] 13 with biologic agents and anticoagulants used in selected cases on appropriate subspecialty advice. There have been a small number of deaths, but generally the outcomes have been good, with few patients requiring extracorporeal membrane oxygenation. The long-term cardiovascular outcomes are yet to be determined.

Interestingly, in early April clinicians in the USA reported a case of KD with concurrent COVID-19, 16 and paediatricians in France and Italy (both of which have had high incidence of SARS-CoV-2 infection) reported marked increases in KD diagnoses (without shock but with positive SARS-COV-2 testing). 7, 8 Many of the cases reported had incomplete KD with fever and less than four of the cardinal 5 clinical features of KD. 7, 8 However, other regions have not reported any increases in KD overall during the pandemic. In Australia and New Zealand, where community transmission and incidence of SARS-CoV-2 remains low, there has not been any change in expected KD incidence in 2020 to date in as yet unpublished national surveillance data (http://www.paeds.org.au/ covid-19-kawasaki-disease-kd-and-pims-ts-children). 17 Reported, but distributive shock predominates 31, 32 Ventricular function abnormality in 31% 9 or 7/8. 13 Between 40 and 62% with shock had impaired EF 7,9 Laboratory findings Total leukocyte count N/" 9,18,26 " 9,26 N/" 9,21 N/# 7, 9 Neutrophil count N/" 9,18,26 " 9,26 N/" 9,21 N/" 7, 9 Lymphocyte count N 9,18 N 9 """ 9,28 ## 7,9

Haemoglobin N/# 9,26 N/# 9,26 # 9,21,28 # 7,9 Platelet count N, "" in 2nd-3rd week 18 # in severe cases 18 ", however # more common than in KD 9,21,27 # 9,21,28 # 7,9

Fibrinogen " initially, normalises rapidly 33, 34 N/" 26 BNP, brain natriuretic peptide; CRP, C-reactive protein; EF, ejection fraction; ESR, erythrocyte sedimentation rate; PCR, polymerase chain reaction; SAG, superantigen; TNF, tissue necrosis factor.

At present, little is known about PIMS-TS. It is unclear whether PIMS-TS represents a severe form of KD triggered by SARS-CoV-2, or a separate entity with a spectrum of disease extending from a mild febrile illness through a KD-like illness to a severe KSS/TSS-like disease. As KD, KSS and TSS are all syndromic, with no diagnostic test, as shown by Whittaker et al., 9 it is difficult to define the boundaries between these phenotypes (Table 1) .

We suggest that clinicians should be aware of this new condition and in the current pandemic should consider PIMS-TS when assessing children with fever and a differential diagnosis of KD, TSS, fever and rash, severe abdominal pain or shock without obvious cause. As with any serious paediatric condition, clinicians should follow recommended clinical management pathways for COVID-19, KD or TSS. For any patient with these conditions suspected to have PIMS-TS, it is important to ensure testing for SARS-CoV-2 by PCR on appropriate specimens but to also collect a blood sample for testing of antibodies (serology) to SARS-CoV-2 prior to IVIG therapy along with convalescent serology. Suspected cases should be discussed with local specialist paediatric services (infectious diseases, rheumatology, intensive care, cardiology) as appropriate.

In Australia and New Zealand, few if any cases of PIMS-TS would be expected as community transmission of SARS-CoV-2 is lowparticularly in children. Nevertheless, the Paediatric Active Enhanced Disease Surveillance network, which already conducts national surveillance for KD and other conditions relevant to paediatrics (www.paeds.org.au) and The Influenza Complications Alert Network are working to establish active surveillance for PIMS-TS in Australia. These groups will be collaborating with other networks to ensure cases of PIMS-TS are rapidly detected and comprehensively investigated. For further information about surveillance and standardised data collection, please refer to http://www.paeds.org.au/covid-19-kawasaki-disease-kd-andpims-ts-children

European Centre for Disease Prevention and Control. Paediatric Inflammatory Multisystem Syndrome and SARS-CoV-2 Infection in Children

Center for Disease Control and Prevention

Multisystem Inflammatory Syndrome in Children and Adolescents with COVID-19. Geneva: World Health Organization

Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children

Epidemiology of COVID-19 among children in China

Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study

Outbreak of kawasaki disease in children during COVID-19 pandemic: A prospective observational study in

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations

Kawasaki disease: What is the epidemiology telling us about the etiology?

Kawasaki disease lacks association with human coronavirus NL63 and human Bocavirus

Hyperinflammatory shock in children during COVID-19 pandemic

Hospitalizations for Kawasaki syndrome among children in the United States

Epidemiology of Kawasaki disease in Asia, Europe, and the United States

COVID-19 and Kawasaki disease: Novel virus and novel case

Paediatric Active Enhanced Surveillance. COVID-19, Kawasaki Disease (KD) and PIMS-TS in Children

Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association

Toxic shock syndrome and bacterial superantigens: An update

Incidence and outcomes of Kawasaki shock syndrome in United States

Early differentiation of Kawasaki disease shock syndrome and toxic shock syndrome in a pediatric intensive care unit

The treatment of Kawasaki syndrome with intravenous gamma globulin

Kawasaki disease: An unexpected etiology of shock and multiple organ dysfunction syndrome

Toxic shock syndrome in the United States: Surveillance update

The genetics of Kawasaki disease

Recognition of a Kawasaki disease shock syndrome

Kawasaki disease in a pediatric intensive care unit: A casecontrol study

Clinical manifestations of toxic shock syndrome

Renal manifestations of the staphylococcal toxic-shock syndrome

Capillary leak leading to shock in Kawasaki disease without myocardial dysfunction

Acute reversible cardiomyopathy complicating toxic shock syndrome

Stunned myocardium in the toxic shock syndrome

Studies on blood coagulation and antithrombotic therapy in Kawasaki disease

Kawasaki disease shock syndrome: Clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition

Impact of increased D-dimer concentrations in Kawasaki disease

Elevated Ddimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease: Risk factors for coronary artery lesions in Kawasaki disease

Kawasaki disease in Sicily: Clinical description and markers of disease severity

Coronary artery dilatation in toxic shock-like syndrome: The Kawasaki disease shock syndrome

Association between a novel human coronavirus and Kawasaki disease

Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease

Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy